» Articles » PMID: 17440071

P21-activated Protein Kinase is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving C-Jun NH2-terminal Kinase Activation and Paxillin Phosphorylation

Overview
Journal Cancer Res
Specialty Oncology
Date 2007 Apr 19
PMID 17440071
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the major malignancies in the world. The prognosis of HCC is poor, due to frequent intrahepatic metastasis and tumor recurrence. P21-activated protein kinase (Pak1), a main downstream effector of small Rho GTPases, Rac1 and Cdc42, plays an important role in the regulation of cell morphogenesis, motility, mitosis, and angiogenesis. Here, we show that Pak1 gene was overexpressed in human HCCs. Overexpression of Pak1 in human HCCs was associated with more aggressive tumor behavior in terms of more metastatic phenotype and more advanced tumor stages. In addition, HCC cell line stably expressing Pak1 displayed increased cell motility rates and, conversely, knockdown of endogenous Pak1 expression by small interfering RNA reduced the migration rates of HCC cells. In an established metastatic HCC cell line, we found that Pak1 was overexpressed compared with its primary HCC cell line and this overexpression was associated with higher cell motility. Importantly, we found that c-Jun NH(2)-terminal kinase (JNK) was activated in HCC cell lines overexpressing Pak1. Inhibition of the JNK activity by chemical inhibitor significantly reduced the migration rates of HCC cells via attenuation of paxillin phosphorylation at Ser(178). In conclusion, our results document that Pak1 is overexpressed in HCCs and plays an important role in the metastasis of HCC. The mechanism by which Pak1 induces cancer metastasis may involve activation of JNK and phosphorylation of paxillin.

Citing Articles

Golgi defect as a major contributor to lysosomal dysfunction.

Akaaboune S, Wang Y Front Cell Dev Biol. 2024; 12:1386149.

PMID: 38721528 PMC: 11076776. DOI: 10.3389/fcell.2024.1386149.


Targeting Heme Oxygenase 2 (HO2) with TiNIR, a Theragnostic Approach for Managing Metastatic Non-Small Cell Lung Cancer.

Mun S, Sim H, Lee J, Kim H, Park D, Lee Y Biomater Res. 2024; 28:0026.

PMID: 38665698 PMC: 11045274. DOI: 10.34133/bmr.0026.


Adverse clinical outcomes and immunosuppressive microenvironment of RHO-GTPase activation pattern in hepatocellular carcinoma.

Yang Q, Zhuo Z, Qiu X, Luo R, Guo K, Wu H J Transl Med. 2024; 22(1):122.

PMID: 38297333 PMC: 10832138. DOI: 10.1186/s12967-024-04926-0.


Clinical Significance of Combined Epithelial-Mesenchymal Transition Markers Expression and Role of Rac1 in Hepatocellular Carcinoma.

Shin S, Ryu S, Nam S, Ha S, Kwon O, Kim Y Int J Mol Sci. 2023; 24(2).

PMID: 36675278 PMC: 9865966. DOI: 10.3390/ijms24021765.


P-21 Activated Kinases in Liver Disorders.

Qiu X, Xu H, Wang K, Gao F, Xu X, He H Cancers (Basel). 2023; 15(2).

PMID: 36672500 PMC: 9857091. DOI: 10.3390/cancers15020551.